|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IGHG2 |
Gene summary for IGHG2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IGHG2 | Gene ID | 3501 |
| Gene name | immunoglobulin heavy constant gamma 2 (G2m marker) | |
| Gene Alias | IGHG2 | |
| Cytomap | 14q32.33 | |
| Gene Type | other | GO ID | GO:0001775 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3501 | IGHG2 | C04 | Human | Oral cavity | OSCC | 2.79e-03 | 1.22e-01 | 0.2633 |
| 3501 | IGHG2 | C38 | Human | Oral cavity | OSCC | 3.06e-14 | 1.50e+00 | 0.172 |
| 3501 | IGHG2 | C46 | Human | Oral cavity | OSCC | 2.44e-17 | 1.63e-01 | 0.1673 |
| 3501 | IGHG2 | C51 | Human | Oral cavity | OSCC | 3.45e-09 | 5.50e-01 | 0.2674 |
| 3501 | IGHG2 | C57 | Human | Oral cavity | OSCC | 3.84e-15 | 3.95e+00 | 0.1679 |
| 3501 | IGHG2 | C08 | Human | Oral cavity | OSCC | 2.38e-12 | 2.08e-01 | 0.1919 |
| 3501 | IGHG2 | C09 | Human | Oral cavity | OSCC | 1.82e-21 | 5.07e-01 | 0.1431 |
| 3501 | IGHG2 | LN22 | Human | Oral cavity | OSCC | 1.21e-22 | 1.95e+00 | 0.1733 |
| 3501 | IGHG2 | LP15 | Human | Oral cavity | LP | 5.38e-19 | 2.11e+00 | 0.2174 |
| 3501 | IGHG2 | LP17 | Human | Oral cavity | LP | 3.16e-02 | 4.72e-01 | 0.2349 |
| 3501 | IGHG2 | Adj_PTCwithHT_6 | Human | Thyroid | HT | 1.95e-55 | 1.64e+00 | 0.02 |
| 3501 | IGHG2 | Adj_PTCwithHT_8 | Human | Thyroid | HT | 1.12e-47 | 1.47e+00 | 0.0267 |
| 3501 | IGHG2 | PTCwithHT_1 | Human | Thyroid | HT | 1.58e-06 | 7.41e-01 | 0.0238 |
| 3501 | IGHG2 | PTCwithHT_6 | Human | Thyroid | HT | 1.82e-132 | 2.29e+00 | 0.02 |
| 3501 | IGHG2 | PTCwithHT_8 | Human | Thyroid | HT | 9.00e-45 | 1.47e+00 | 0.0351 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00027646 | Oral cavity | OSCC | immune response-regulating signaling pathway | 212/7305 | 468/18723 | 2.93e-03 | 1.27e-02 | 212 |
| GO:00512519 | Thyroid | HT | positive regulation of lymphocyte activation | 51/1272 | 362/18723 | 5.57e-07 | 2.38e-05 | 51 |
| GO:000269610 | Thyroid | HT | positive regulation of leukocyte activation | 55/1272 | 409/18723 | 9.17e-07 | 3.70e-05 | 55 |
| GO:00508679 | Thyroid | HT | positive regulation of cell activation | 55/1272 | 420/18723 | 2.11e-06 | 7.61e-05 | 55 |
| GO:00160644 | Thyroid | HT | immunoglobulin mediated immune response | 32/1272 | 207/18723 | 1.05e-05 | 2.82e-04 | 32 |
| GO:00197244 | Thyroid | HT | B cell mediated immunity | 32/1272 | 210/18723 | 1.42e-05 | 3.57e-04 | 32 |
| GO:00024494 | Thyroid | HT | lymphocyte mediated immunity | 45/1272 | 350/18723 | 2.76e-05 | 6.05e-04 | 45 |
| GO:00022536 | Thyroid | HT | activation of immune response | 47/1272 | 375/18723 | 3.55e-05 | 7.40e-04 | 47 |
| GO:00069564 | Thyroid | HT | complement activation | 22/1272 | 130/18723 | 6.17e-05 | 1.16e-03 | 22 |
| GO:00069598 | Thyroid | HT | humoral immune response | 40/1272 | 317/18723 | 1.14e-04 | 1.86e-03 | 40 |
| GO:00024434 | Thyroid | HT | leukocyte mediated immunity | 51/1272 | 440/18723 | 1.30e-04 | 2.07e-03 | 51 |
| GO:00080371 | Thyroid | HT | cell recognition | 31/1272 | 225/18723 | 1.35e-04 | 2.12e-03 | 31 |
| GO:00024605 | Thyroid | HT | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 43/1272 | 356/18723 | 1.74e-04 | 2.59e-03 | 43 |
| GO:00421133 | Thyroid | HT | B cell activation | 39/1272 | 334/18723 | 6.66e-04 | 7.61e-03 | 39 |
| GO:00069583 | Thyroid | HT | complement activation, classical pathway | 17/1272 | 108/18723 | 9.56e-04 | 9.83e-03 | 17 |
| GO:00027648 | Thyroid | HT | immune response-regulating signaling pathway | 50/1272 | 468/18723 | 9.96e-04 | 1.02e-02 | 50 |
| GO:00024552 | Thyroid | HT | humoral immune response mediated by circulating immunoglobulin | 18/1272 | 121/18723 | 1.35e-03 | 1.29e-02 | 18 |
| GO:00069094 | Thyroid | HT | phagocytosis | 34/1272 | 308/18723 | 3.59e-03 | 2.73e-02 | 34 |
| GO:00103244 | Thyroid | HT | membrane invagination | 19/1272 | 144/18723 | 4.08e-03 | 2.99e-02 | 19 |
| GO:00508643 | Thyroid | HT | regulation of B cell activation | 24/1272 | 198/18723 | 4.18e-03 | 3.05e-02 | 24 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IGHG2 | SNV | Missense_Mutation | rs774491393 | c.550N>A | p.Val184Ile | p.V184I | P01859 | IG_C_gene | tolerated(0.33) | benign(0.022) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
| IGHG2 | SNV | Missense_Mutation | rs375068368 | c.571N>A | p.Asp191Asn | p.D191N | P01859 | IG_C_gene | deleterious(0) | benign(0.415) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| IGHG2 | SNV | Missense_Mutation | rs368453065 | c.433N>A | p.Val145Met | p.V145M | P01859 | IG_C_gene | tolerated(0.09) | possibly_damaging(0.547) | TCGA-A6-3808-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| IGHG2 | SNV | Missense_Mutation | rs774491393 | c.550N>A | p.Val184Ile | p.V184I | P01859 | IG_C_gene | tolerated(0.33) | benign(0.022) | TCGA-AA-3844-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | PD |
| IGHG2 | SNV | Missense_Mutation | rs745454231 | c.401N>A | p.Arg134Gln | p.R134Q | P01859 | IG_C_gene | tolerated(0.38) | benign(0.015) | TCGA-AA-3939-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| IGHG2 | SNV | Missense_Mutation | novel | c.226T>G | p.Phe76Val | p.F76V | P01859 | IG_C_gene | deleterious(0.02) | benign(0) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| IGHG2 | SNV | Missense_Mutation | novel | c.187T>C | p.Tyr63His | p.Y63H | P01859 | IG_C_gene | deleterious(0.03) | probably_damaging(0.999) | TCGA-AA-3979-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| IGHG2 | SNV | Missense_Mutation | novel | c.611N>G | p.Asn204Ser | p.N204S | P01859 | IG_C_gene | tolerated(0.29) | benign(0.092) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| IGHG2 | SNV | Missense_Mutation | novel | c.174N>C | p.Gln58His | p.Q58H | P01859 | IG_C_gene | tolerated(0.07) | probably_damaging(0.993) | TCGA-AZ-6607-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| IGHG2 | SNV | Missense_Mutation | rs368453065 | c.433N>A | p.Val145Met | p.V145M | P01859 | IG_C_gene | tolerated(0.09) | possibly_damaging(0.547) | TCGA-DY-A1H8-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |